States want what Roche still has to offer; ScinoPharma plans cancer drug plant; Pfizer pays out 295th quarterly dividend;

@FiercePharma: So, what's with all the drug names ending in "IQ"? Astellas' Myrbetriq, Arena's Belviq ... Did Pfizer's Pristiq start a trend? | Follow @FiercePharma

> For the 295th time in a row, Pfizer ($PFE) has declared a quarterly dividend, this time for 22 cents a share, payable Sept. 5, to shareholders as of Aug. 3. Release

> Gilead Sciences said Thursday that it asked the FDA to approve its drug cobicistat, a component of its proposed four-in-one HIV pill. Item

> Bedford Laboratories is voluntarily recalling at the hospital and user level lot 2067134 of Vecuronium Bromide for Injection preservative free, because particulates have been found in a small number of vials. Item

> Biogen Idec and Isis Pharmaceuticals will form a second alliance, this time to develop a treatment for myotonic dystrophy type 1 (DM1), sometimes called Steinert disease. Story

ScinoPharm will spend about $37.5 million on an injectable cancer drug manufacturing plant in Taiwan that it says will be completed in 2014. Story

Biotech News

@FierceBiotech: At GSK, there are no corner offices, or any other. More | Follow @FierceBiotech

@JohnCFierce: Icahn step 5: Sue Forest over succession plan. More | Follow @JohnCFierce

> Biogen Idec offers up to $271M for its second Isis pact. Story

> Astellas nabs critical FDA OK for new overactive bladder pill mirabegron. Article

> BioInvent forced to reorganize, ax staffers in wake of study failure. News

Medical Device News

@FierceMedDev: We have extended the nomination deadline for the 15 fiercest medical device developers to July 13. Spread the word. Survey | Follow @FierceMedDev

> MHRA warns of reusable device contamination. Article

> FDA panel recommends against metal-on-metal hip implants. News

> FSS gets CE mark for self-expanding stent. Story

> Study: iPad use could muddle shunt settings. Study

And Finally... The announcement by Roche that it will establish a new clinical research center on the East Coast already has the eco-devo folks across the Eastern Seaboard salivating. Story